Qiagen N.V. (QGEN)

Qiagen N.V. (QGEN) Healthcare & Pipeline Overview

QIAGEN N.V., founded in 1986, provides sample to insight solutions, converting biological materials into valuable molecular insights. Serving molecular diagnostics, academia, pharmaceutical, and applied testing sectors, the company offers a comprehensive portfolio of consumables, instruments, and services, maintaining a strong position in the global diagnostics and research market.

What Is the Investment Thesis for QGEN?

QIAGEN N.V. presents a compelling investment case driven by its established position in the molecular diagnostics and research market. With a P/E ratio of 19.3 and a profit margin of 19.2%, QIAGEN demonstrates financial stability. The company's growth is underpinned by increasing demand for molecular testing and personalized medicine. Key catalysts include expanding its NGS offerings and strategic partnerships. However, potential risks include competition from other diagnostics companies and regulatory changes in the healthcare sector. The company's dividend yield of 7.69% also provides an attractive return for investors.

Based on FMP financials and quantitative analysis

QGEN Key Highlights

• Market Cap of $8.04B reflects QIAGEN's significant presence in the diagnostics and research market.
• P/E Ratio of 19.3 indicates a reasonable valuation compared to earnings.
• Profit Margin of 19.2% demonstrates strong profitability and operational efficiency.
• Gross Margin of 61.5% highlights the company's ability to maintain high margins on its products and services.
• Dividend Yield of 7.69% provides a substantial return for investors, showcasing the company's commitment to shareholder value.

Who Are QGEN's Competitors?

QGEN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are QGEN's Key Strengths?

• Comprehensive portfolio of sample to insight solutions.
• Strong brand reputation and customer loyalty.
• Global presence and distribution network.
• High gross margin and profitability.

What Are QGEN's Weaknesses?

• Dependence on research and development for new products.
• Exposure to regulatory changes and healthcare policies.
• Competition from larger and more diversified companies.
• Potential for product recalls or quality issues.

What Could Drive QGEN Stock Higher?

• Expansion of NGS (Next-Generation Sequencing) offerings to drive revenue growth.
• Strategic partnerships and collaborations to expand market reach.
• Increasing demand for molecular diagnostics in emerging markets.
• Launch of new assays and technologies for infectious diseases and personalized medicine.
• Continued investment in research and development to maintain competitive edge.

What Are the Key Risks for QGEN?

• Competition from other diagnostics companies could lead to pricing pressures.
• Regulatory changes in the healthcare sector could impact product approvals and reimbursement.
• Technological obsolescence could render existing products and services less competitive.
• Economic downturns and reduced healthcare spending could negatively affect demand for QIAGEN's products.
• Product recalls or quality issues could damage the company's reputation and financial performance.

What Are the Growth Opportunities for QGEN?

• Expansion of NGS (Next-Generation Sequencing) Offerings: QIAGEN can capitalize on the rapidly growing NGS market by expanding its portfolio of NGS gene panels, library prep kits, and bioinformatics solutions. The global NGS market is projected to reach $25 billion by 2028, driven by increasing adoption in research, diagnostics, and personalized medicine. QIAGEN's competitive advantage lies in its integrated solutions, combining consumables, instruments, and software for NGS workflows. Timeline: Ongoing.
• Strategic Partnerships and Collaborations: QIAGEN can leverage strategic partnerships and collaborations to expand its market reach and enhance its product offerings. The company's existing alliances with Sysmex Corporation and OncXerna Therapeutics demonstrate its ability to forge successful partnerships. By collaborating with other companies, QIAGEN can access new technologies, markets, and customer segments. Timeline: Ongoing.
• Growth in Molecular Diagnostics Market: The increasing demand for molecular diagnostics presents a significant growth opportunity for QIAGEN. The global molecular diagnostics market is expected to reach $15 billion by 2027, driven by factors such as the rising prevalence of infectious diseases, cancer, and genetic disorders. QIAGEN's comprehensive portfolio of molecular diagnostic assays and instruments positions it well to capitalize on this growth. Timeline: Ongoing.
• Penetration of Emerging Markets: QIAGEN can expand its presence in emerging markets, such as Asia-Pacific and Latin America, where healthcare spending is increasing and demand for advanced diagnostics is growing. These markets offer significant growth potential for QIAGEN's products and services. By establishing a strong presence in these regions, QIAGEN can diversify its revenue streams and reduce its reliance on developed markets. Timeline: Ongoing.
• Development of New Assays and Technologies: QIAGEN can drive growth by investing in the development of new assays and technologies that address unmet needs in the diagnostics and research markets. This includes developing assays for emerging infectious diseases, personalized medicine applications, and novel biomarkers. By continuously innovating and expanding its product portfolio, QIAGEN can maintain its competitive edge and attract new customers. Timeline: Ongoing.

What Opportunities Does QGEN Have?

• Expansion into emerging markets.
• Development of new assays and technologies.
• Strategic acquisitions and partnerships.
• Increasing demand for molecular diagnostics and personalized medicine.

What Threats Does QGEN Face?

• Competition from other diagnostics companies.
• Pricing pressures from healthcare providers and payers.
• Technological obsolescence.
• Economic downturns and reduced healthcare spending.

What Are QGEN's Competitive Advantages?

• Proprietary technologies in sample preparation and analysis.
• Established brand reputation and customer relationships.
• Extensive portfolio of products and services.
• Strategic alliances and partnerships.

What Does QGEN Do?

QIAGEN N.V., established in 1986 and headquartered in Venlo, Netherlands, is a global provider of sample to insight solutions. The company transforms biological materials into valuable molecular insights through its comprehensive range of products and services. QIAGEN serves a diverse customer base, including molecular diagnostics laboratories, academic research institutions, pharmaceutical companies, and applied testing facilities. Its offerings span from sample collection to data analysis, enabling customers to unlock critical information from biological samples. QIAGEN's product portfolio includes primary sample technology consumables, such as nucleic stabilization and purification kits, and secondary sample technology consumables for purifying nucleic acids from secondary sample materials. The company also provides a wide array of instruments for nucleic acid purification and accessories, including automated processing systems for genotyping, gene expression, and viral/bacterial analysis. Additionally, QIAGEN offers assays for TB testing, post-transplant monitoring, viral load monitoring, prenatal testing, sexually transmitted disease detection, HPV detection, and genomic variant analysis. QIAGEN's sample to insight instruments facilitate one-step molecular analysis of hard-to-diagnose syndromes and integrated PCR testing. The company also provides PCR consumables, human ID and forensics assay consumables, and PCR instruments, including digital PCR solutions. Furthermore, QIAGEN offers NGS gene panels, library prep kits, bioinformatics solutions, and custom laboratory and genomic services. The company has strategic alliances with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati, enhancing its capabilities and market reach.

What Products and Services Does QGEN Offer?

• Provides nucleic stabilization and purification kits for primary sample materials.
• Offers manual and automated processing for genotyping, gene expression, and viral and bacterial analysis.
• Develops and manufactures instruments for nucleic acid purification and accessories.
• Offers interferon-gamma release assay for TB testing.
• Provides assays for post-transplant testing and viral load monitoring.
• Develops assays for prenatal testing and detection of sexually transmitted diseases and HPV.
• Offers predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification.
• Provides bioinformatics solutions and custom laboratory and genomic services.

How Does QGEN Make Money?

• Sale of consumables, including kits and reagents for sample preparation and analysis.
• Sale of instruments, such as automated platforms for nucleic acid purification and PCR.
• Provision of services, including custom assay development and bioinformatics analysis.
• Strategic alliances and partnerships to expand market reach and product offerings.

What Industry Does QGEN Operate In?

QIAGEN N.V. operates in the medical diagnostics and research industry, which is experiencing growth driven by advancements in molecular biology and personalized medicine. The market is characterized by increasing demand for diagnostic testing, driven by factors such as aging populations, rising prevalence of chronic diseases, and growing awareness of preventive healthcare. QIAGEN competes with companies like RVTY: Revvity, Inc. that offer similar diagnostic and research solutions. The industry is also subject to regulatory oversight and technological advancements, requiring companies to continuously innovate and adapt to changing market dynamics.

Who Are QGEN's Key Customers?

• Molecular diagnostics laboratories
• Academic research institutions
• Pharmaceutical companies
• Applied testing facilities

FY2026 estForward Outlook

Wall Street analysts project Qiagen N.V. revenue of about $2.15B for fiscal 2026, with EPS near $2.42. The estimate reflects 12 contributing analysts.

QGEN Valuation & Market Position

With a $8.04B market cap, Qiagen N.V. sits in the mid-cap segment of the market. Relative to its peer group, QGEN's quantitative score of 56/100 is below the peer average of 84/100.

ROE 11%Key Financial Metrics

Return on equity for Qiagen N.V. stands at 11.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.0%, showing how much profit it generates from its asset base. QGEN trades at a trailing price-to-earnings ratio of 19.26, below the Healthcare sector average of ~23x. Its free cash flow yield is 5.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.21 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.8%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 5/9Financial Health

Qiagen N.V.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.57 places it in the safe zone, indicating low near-term bankruptcy risk.

Company Profile

Qiagen N.V. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Venlo, US. The company is led by CEO Thierry L. Bernard. QGEN has traded publicly since 1996.

QGEN Financials

QGEN Latest News

QGEN Analyst Consensus

QGEN MoonshotScore

What Investors Ask About Qiagen N.V. (QGEN) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources